Know Cancer

forgot password

A Phase II Study of Preemptive Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions for Achieving Complete Donor Chimerism Following Allogeneic Transplant for Pediatric Hematologic Malignancies

Phase 2
6 Months
25 Years
Open (Enrolling)
Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia, Pre-leukemic Syndromes, Monosomy 7, Bone Marrow Clonal Malformations, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia

Thank you

Trial Information

A Phase II Study of Preemptive Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions for Achieving Complete Donor Chimerism Following Allogeneic Transplant for Pediatric Hematologic Malignancies

The goal of this Phase II study is to identify if achieving full donor chimerism in whole
blood, CD3+, and leukemia-specific subset (CD3+, CD14/15+, CD19+, CD33+ and CD34+ subset)
may decrease the risk of relapse of patients undergoing allogeneic transplant for
hematologic malignancy.

We estimate that total of 50 recipient patients will need to be enrolled. Of these 50
recipient patients an observation group and an intervention group will be formed. We want
to enroll 25 recipient patients in the intervention group, this group will receive study
intervention and their outcomes will be the focus of statistical analysis for this study.
Intervention will involve fast withdrawal of immunosuppression following transplant and
donor lymphocyte infusion (DLI) until full donor chimerism is achieved. Chimerism is a
genetic test that measures the proportion of donor's and recipient's cells in blood or bone
marrow. Twenty five patients will undergo fast withdrawal of immunosuppression and 33 -50%
of them (8-13) will undergo DLI following fast withdrawal of immunosuppression.

Patients will have peripheral blood (PB) chimerism tested upon engraftment. A confirmatory
test from PB and bone marrow (BM) will be done on day 45±7. Minimal residual disease (MRD)
will be examined by immunoflow, FISH, cytogenetics or PCR. Patients with positive MRD will
be on a faster schedule of immune intervention than patients with negative MRD.
Interventions will be carried on until 1 year post transplant. If confirmatory testing shows
no evidence of MRD and full donor chimerism is present in all subsets, the patient will be
part of the "observation" group and be observed until 2 years post transplant. Chimerism
will be repeated at 12 and 24 months post transplant. If the patient has mixed chimerism on
both confirmatory tests (PB and BM), the patient will be part of the "intervention" group
and fast withdrawal of immunosuppression will be initiated. If the patient has mixed
chimerism on one of the confirmatory tests (PB or BM), the test will be repeated in 2 weeks
and the patient will proceed with either observation or intervention, based on the result of
the repeated test. Patients will be followed for the incidence of acute and chronic Graft
Versus Host Disease (GVHD) and relapse until 2 years post transplant. The study will be
considered successful if the relapse rate at 2 years post transplant is ≤20% for the entire
study or ≤ 40% for the intervention group.

Inclusion Criteria:

- Age 6 months - 25 years.

- Diagnoses of acute leukemia (AML, ALL, biphenotypic leukemia), pre-leukemic syndromes
(monosomy 7 or other bone marrow clonal malformations), JMML, myelodysplastic
syndromes or CML.

- Undergoing an allogeneic transplant as standard care.

- Performance status: Karnofsky/Lansky>60%.

- Availability of pre-transplant recipient's DNA and donor's DNA for chimerism testing.
This could be DNA or material from which DNA could be extracted. Frozen blood would
be preferred. For some patients, post transplant specimens that are not infiltrated
with donor cells may be used.

- Bone marrow or PBMTC as stem cell source.HLA matching: donor and recipient should be
matched at a minimum of 7/8 antigens (A,B,C and DrB1) for bone marrow and PBMTC

- No history of ≥grade III acute GVHD.

Exclusion Criteria:

- Treatment on other experimental protocols, if withdrawal of immunosuppression
interferes with procedures of follow-up on the primary study.

- Leukemia relapse defined as > 5% blasts on bone marrow exam or >1% leukemia cells by
immunoflow MRD, or presence of extramedullary leukemia.

- History of acute GVHD ≥ stage III or with any degree of active acute or cGVHD.

- On steroids for any reason.

- Any condition that compromises compliance with the objectives and procedures of this
protocol, as judged by the principal investigator.

- Cells for DLI cannot be obtained from the donor.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Relapse rate at 2 years post-transplant.

Outcome Time Frame:

2 years post transplant.

Safety Issue:


Principal Investigator

Biljana Horn, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, San Francisco


United States: Institutional Review Board

Study ID:

CC# 09082



Start Date:

October 2009

Completion Date:

September 2016

Related Keywords:

  • Acute Leukemia
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Biphenotypic Leukemia
  • Pre-leukemic Syndromes
  • Monosomy 7
  • Bone Marrow Clonal Malformations
  • Juvenile Myelomonocytic Leukemia
  • Myelodysplastic Syndromes
  • Chronic Myelogenous Leukemia
  • Hematologic
  • Malignancy
  • Leukemia
  • Pre-leukemic
  • Allogeneic
  • Transplant
  • Pediatric
  • Congenital Abnormalities
  • Neoplasms
  • Leukemia
  • Leukemia, Lymphoid
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Monosomy
  • Myelodysplastic Syndromes
  • Preleukemia
  • Leukemia, Myelomonocytic, Acute
  • Leukemia, Myelomonocytic, Chronic
  • Leukemia, Myelomonocytic, Juvenile
  • Hematologic Neoplasms



All Children's Hospital St. Petersburg, Florida  33701
University of California San Francisco, California  94108